Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Payables: 2023-2025

Historic Payables for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $12.3 million.

  • Tonix Pharmaceuticals Holding's Payables rose 51.29% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.8 million, marking a year-over-year increase of 0.07%. This contributed to the annual value of $10.7 million for FY2024, which is 14.54% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Payables stood at $12.3 million, which was up 11.27% from $11.1 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Payables peaked at $12.5 million during Q4 2023, and registered a low of $7.7 million during Q1 2025.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Payables averaged around $10.1 million, with its median value being $10.4 million (2024).
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Payables showed a top increase of 51.29% in 2025 and a maximum decrease of 28.09% in 2025.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Payables stood at $12.5 million in 2023, then declined by 14.54% to $10.7 million in 2024, then surged by 51.29% to $12.3 million in 2025.
  • Its Payables was $12.3 million in Q3 2025, compared to $11.1 million in Q2 2025 and $7.7 million in Q1 2025.